[go: up one dir, main page]

MX2015011462A - Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. - Google Patents

Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.

Info

Publication number
MX2015011462A
MX2015011462A MX2015011462A MX2015011462A MX2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A MX 2015011462 A MX2015011462 A MX 2015011462A
Authority
MX
Mexico
Prior art keywords
cholestosome
present
patient
ability
molecules
Prior art date
Application number
MX2015011462A
Other languages
English (en)
Other versions
MX384232B (es
Inventor
Jerome J Schentag
Mary P Mccourt
Lawrence Mielnicki
Julie Hughes
Original Assignee
Jerome J Schentag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015011462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jerome J Schentag filed Critical Jerome J Schentag
Publication of MX2015011462A publication Critical patent/MX2015011462A/es
Publication of MX384232B publication Critical patent/MX384232B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

La presente invención está dirigida a una nanopartícula de éster de colesterilo portadora de carga, con un compartimento hueco (cholestosome: colestosoma), que esencialmente consiste en al menos un éster de colesterilo no iónico y una o más moléculas activas encapsuladas, el cual no puede pasar apreciablemente a través de una membrana enterocítica en ausencia de la molécula que se carga en el colestosoma, el colestosoma tiene una superficie neutra y la capacidad de pasar a los enterocitos como lo hacen los lípidos nutrientes absorbidos por vía oral que utilizan las vías celulares para llegar al aparato de Golgi. Según la presente invención, los nuevos colestosomas portadores de carga según la presente invención, tienen la capacidad de depositar moléculas activas dentro de las células de un paciente o de un individuo y realizar tratamiento o diagnóstico en el paciente o el individuo.
MX2015011462A 2013-03-14 2014-03-14 Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones. MX384232B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783003P 2013-03-14 2013-03-14
PCT/US2014/027761 WO2014152795A2 (en) 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons

Publications (2)

Publication Number Publication Date
MX2015011462A true MX2015011462A (es) 2016-05-31
MX384232B MX384232B (es) 2025-03-14

Family

ID=51581747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011462A MX384232B (es) 2013-03-14 2014-03-14 Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.

Country Status (10)

Country Link
US (6) US9693968B2 (es)
EP (1) EP2970369B1 (es)
JP (2) JP2016513712A (es)
CN (1) CN105164143B (es)
AU (1) AU2014236559B2 (es)
BR (1) BR112015022936A2 (es)
CA (1) CA2905108C (es)
IL (1) IL241501B (es)
MX (1) MX384232B (es)
WO (1) WO2014152795A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
US9693968B2 (en) 2013-03-14 2017-07-04 Jerome J. Schentag Cholestosome vesicles for incorporation of molecules into chylomicrons
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
WO2016054399A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microrna-26a
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
JP7026044B2 (ja) 2015-12-23 2022-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ－１ｒアゴニスト
CN105797132A (zh) * 2016-05-03 2016-07-27 滨州医学院 沙奎拉韦的医药新用途
AU2017315321A1 (en) * 2016-08-23 2019-04-11 Mary P. Mccourt Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
CN107260681A (zh) * 2017-08-04 2017-10-20 济南维瑞医药科技开发有限公司 一种磷酸特地唑胺脂质体的制备方法及其应用
US11504325B2 (en) 2017-08-09 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Micelles and vesicles for the delivery of glycopeptides
US12478585B2 (en) 2017-08-09 2025-11-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Micelles and vesicles for the delivery of glycopeptides
AU2018363883B2 (en) * 2017-11-09 2024-11-14 Meizon Innovation Pty Ltd Methods for evaluating and improving cognitive function
WO2019119673A1 (zh) * 2017-12-19 2019-06-27 北京吉源生物科技有限公司 一种双基因修饰的干细胞及其用途
CN112074286A (zh) 2018-01-23 2020-12-11 吉拉毒蜥治疗公司 肽yy药物制剂、组合物和方法
EP3768829A4 (en) 2018-02-01 2022-02-09 The Royal Institution for the Advancement of Learning / McGill University FORMULATIONS TO ENHANCE DELIVERY OF HYDROPHOBIC AGENTS
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN110638788A (zh) * 2019-10-25 2020-01-03 广州医科大学 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2023543037A (ja) * 2020-09-25 2023-10-12 アルゴリズム サイエンシズ，インコーポレイテッド 血管拡張剤送達のための組成物及び方法
JP7505831B2 (ja) * 2021-12-14 2024-06-25 シード医療製薬株式会社 海藻抽出物を含む高血圧症改善剤並びに同高血圧症改善剤を含む機能性食品、医薬部外品及び医薬品
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
AU2023238223A1 (en) 2022-03-23 2024-10-10 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles
CN119837820B (zh) * 2023-12-13 2025-10-10 上海交通大学 一种基于蛋白载体的活性成分透皮递送系统及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
EP0331504B1 (en) 1988-03-04 1992-06-10 Takeda Chemical Industries, Ltd. Liposome composition
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP0937456B1 (en) 1998-02-23 2004-07-21 Cilag AG International Erythropoietin liposomal dispersion
JP4255123B2 (ja) 2002-04-26 2009-04-15 アンジェスＭｇ株式会社 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ）
AU2003237864B2 (en) * 2002-05-15 2008-12-18 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20060216255A1 (en) 2003-04-11 2006-09-28 Kun-Kook Lee Medicinal cosmetical composition with areca catechu seed extract
WO2004098564A2 (en) 2003-05-02 2004-11-18 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
JP2007501850A (ja) 2003-05-09 2007-02-01 ノボソム アーゲー 作用物質のデリバリーのための注射可能なリポソーム式デポー製剤
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US7662405B2 (en) 2005-08-09 2010-02-16 The Research Foundation Of State University Of New York Compositions and methods of preparation of liposomal microparticulate IL-12
US9119782B2 (en) * 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2009051451A2 (en) * 2007-10-17 2009-04-23 Korea Advanced Institute Of Science And Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
NZ589390A (en) * 2008-05-05 2011-11-25 Oramed Ltd Methods and compositions for oral administration of exenatide
EP2282728B1 (en) * 2008-05-22 2015-02-25 H. Lundbeck A/S Modulation of the Vps10p-domain receptors.
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
US9757346B2 (en) 2008-09-03 2017-09-12 Volant Holdings Gmbh Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
JP2009143963A (ja) 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
WO2011115684A2 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110268653A1 (en) 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US8355188B2 (en) 2010-07-27 2013-01-15 Foxlink Image Technology Co., Ltd. Document guiding mechanism
KR20190060879A (ko) 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
US20140199233A1 (en) * 2011-05-11 2014-07-17 The Regents Of The University Of California Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
US9693969B2 (en) 2012-01-02 2017-07-04 Andrew L. SKIGEN Mucous membrane active agent application
CA2868362C (en) 2012-03-29 2018-07-31 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US9693968B2 (en) 2013-03-14 2017-07-04 Jerome J. Schentag Cholestosome vesicles for incorporation of molecules into chylomicrons
CN114533753A (zh) 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
AU2017315321A1 (en) 2016-08-23 2019-04-11 Mary P. Mccourt Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

Also Published As

Publication number Publication date
CA2905108C (en) 2021-12-07
US20200069598A1 (en) 2020-03-05
EP2970369B1 (en) 2023-11-22
US10369114B2 (en) 2019-08-06
AU2014236559A1 (en) 2018-05-24
US20160030361A1 (en) 2016-02-04
EP2970369A2 (en) 2016-01-20
EP2970369A4 (en) 2016-10-12
IL241501B (en) 2020-05-31
CA2905108A1 (en) 2014-09-25
US11633364B2 (en) 2023-04-25
MX384232B (es) 2025-03-14
US20220040116A1 (en) 2022-02-10
US20240398719A1 (en) 2024-12-05
US12005146B2 (en) 2024-06-11
US20180055780A1 (en) 2018-03-01
WO2014152795A3 (en) 2014-11-27
US11052052B2 (en) 2021-07-06
BR112015022936A2 (pt) 2017-07-18
CN105164143A (zh) 2015-12-16
US9693968B2 (en) 2017-07-04
JP2019070031A (ja) 2019-05-09
US12465575B2 (en) 2025-11-11
JP2016513712A (ja) 2016-05-16
US20230277471A1 (en) 2023-09-07
WO2014152795A2 (en) 2014-09-25
AU2014236559B2 (en) 2020-03-12
IL241501A0 (en) 2015-11-30
CN105164143B (zh) 2019-02-19
HK1212354A1 (en) 2016-06-10
JP6688408B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
MX2015011462A (es) Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
DOP2014000159A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
NI201500094A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
GT201500348A (es) Compuestos de pirimidinodiona contra estados cardíacos
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
NI201300041A (es) Antagonistas de mdm2 de espiro-oxindol
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
CU24336B1 (es) Compuestos de imidazopirrolidinona
BR112014013175A2 (pt) composições de liberação prolongada baseadas em lipídios anfipáticos
MX391858B (es) Compuestos terapeuticamente activos y sus metodos de uso
MX2015004524A (es) Metodos y composiciones de nanoplacas de plata.
MX379193B (es) Composiciones en solucion solida y su uso en inflamacion cronica.
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
CL2017002156A1 (es) Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
PE20191713A1 (es) Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
MX361155B (es) Cocleatos hechos con fosfatidilserina de soja.
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
CO7091174A2 (es) Compuestos triazolo como inhibidores de pde10
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX2014014662A (es) Manufactura de degarelix.